ORIGINAL RESEARCH article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1629585
This article is part of the Research TopicVaccines and Breakthrough InfectionsView all 11 articles
Development and Characterization of the Genotype F Attenuated Mumps candidate strains
Provisionally accepted
- 1Changchun Institute of Biological Products Co. Ltd, Changchun, China
- 2Changchun Keygen Biological Products Co., Ltd., Changchun, China
- 3State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Mumps is an acute infectious disease caused by the mumps virus (MuV), mainly affecting the parotid glands, which is also a systemic infection, including the nervous system. Epidemiological data analysis indicates that the predominant genotype of the prevalent MuV strains in China is genotype F while the vaccine strain is genotype A. Immunization effectivity of the genotype A vaccine strains S79 or WM84 has declined as genotype F has been the predominant genotype of mumps virus in mainland China over the past decade. Here, one F-type mumps virus (MuV) genotype F strain was isolated from the throat swabs of six suspected mumps patients. Subsequently, two candidate strains QBB-2BS-3.2 and QBB-2BS-9.3 were prepared using cell adaptation passage and plaque purification. The QBB-2BS-3.2 and QBB-2BS-9.3 could elicit potent neutralizing antibodies against MuV and cell-mediated immune responses in immunized mice. Moreover, the QBB-2BS-3.2 and QBB-2BS-9.3 showed minimal neurotoxicity in neonatal Lewis mice, comparable to S79. In this study, we successfully prepared two genotype F attenuated Mumps candidate strains and evaluated the immunogenicity and neurotoxicity, providing a basis for the development of attenuated live MuV vaccine of genotype F.
Keywords: Mumps virus, F genotype, QBB strain, Immunogenicity, Neurovirulence
Received: 16 May 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Liu, Liu, Sun, Li, Li, Wang, Shuang and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hongtao Liu, Changchun Institute of Biological Products Co. Ltd, Changchun, China
Yan Cai, Changchun Keygen Biological Products Co., Ltd., Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.